Bi N, et al. - The findings in patients with complex brain metastases (BMs) who were administered concurrent temozolomide (TMZ) with hypofractionated stereotactic radiotherapy (HFSRT) in a single institutional phase II trial are reported by the researchers in this present study. This report also addresses the findings concerning feasibility and toxicity. Concurrent HFSRT and TMZ (administrated orally at a dosage of 75 mg/m² per day for at least 20 days) was received by 54 patients with histologically proven primary cancer and complex BMs, enrolled between 2010 and 2015. Overall survival (OS) was considered as primary endpoint. Participants were followed for a median duration of 30.6 months. Good tolerability was seen with treatment using HFSRT concurrent with TMZ. In addition, vs historical controls, this treatment strategy could significantly lengthen OS.